Abstract: Diabetic foot ulceration stands as one of the most costly and debilitating complications of diabetes and remains the leading cause of nontraumatic lower extremity amputation in the United States. Traditionally, ischemia, neuropathy, trauma, and infection were considered the culprits of the recurring chronic wound and treatment revolved largely around wound debridement and revascularization. However, recent investigations have uncovered an impaired cutaneous wound healing process in diabetes caused by cellular and molecular alterations in the diabetic microenvironment and have subsequently identified an array of potential molecular targets for intervention. Here, we review recent patents describing upcoming molecular technologies at various stages of development for treating foot ulceration in the diabetic patient. Target classes reviewed include immunomodulators, neuropeptides, and growth factors, and targets reviewed include lactoferrin, thymosin beta 4, T cell immune response cDNA 7, substance P, neuropeptide Y, vascular endothelial growth factor, fibroblast growth factor, nerve growth factor, connective tissue growth factor, hepatocyte growth factor, homeobox genes, and treprostinil. In the course of this presentation, the biology of wound healing and the pathobiology of impaired wound healing in diabetes are emphasized to illustrate how these future molecular therapeutics are intended to counteract disease pathology and promote normal wound repair.
INTRODUCTION
According to the American Diabetes Association, 7% of the general population and 21% of people over the age of 60 are afflicted with diabetes in the United States [1] . One of the most outward and debilitating complications of diabetes is the development of chronic non-healing foot ulcerations, occurring in 15% of diabetics. In its most unfavorable course, diabetic foot ulceration leads to amputation in 14-24% of afflicted individuals and is the leading cause of nontraumatic lower extremity amputation in the U.S. [2] . The national economic burden of diabetic foot ulceration and amputation is correspondingly staggering, estimated near 11 billion dollars in the year 2001 [3] .
The pathophysiologic trail from hyperglycemia to foot ulceration traverses a complex interplay between multiple dysfunctioning systems. Traditionally, ischemia, neuropathy, trauma, and infection were considered the culprits of the recurring chronic wound and management revolved largely around prevention through glycemic control and cardiovascular risk factor modification [4] , wound debridement, and revascularization [5, 6] . More recently, impairment of the cutaneous wound healing process itself has been recognized as a major contributor to the failure to heal, and wound healing has been appreciated as yet another biological *Address Correspondence to this author at the Microcirculation Laboratory, Beth Israel Deaconess Medical Center, Palmer 317, West Campus, One Deaconess Rd., Boston, MA 02215, USA; Tel: 617-632-7075; Fax: 617-632-0860; E-mail: aveves@bidmc.harvard.edu system hindered by the metabolic, vascular, neurologic, and inflammatory alterations present in diabetes [7] . In light of this recent understanding, numerous investigations are pursuing therapies for diabetic foot ulceration which act to restore the molecular and cellular processes required for successful wound healing.
In this review of recent patents, we will outline some of the most promising new molecular innovations for promoting wound healing in the diabetic patient. In the course of this presentation the biology of wound healing and the pathobiology of impaired wound healing in diabetes will be emphasized to show how these upcoming molecular therapeutics are intended to counteract disease pathology and restore normal wound healing activity.
MECHANISMS OF IMPAIRED WOUND HEALING IN DIABETES
Normal wound healing is a complex cellular response that relies upon the timed release of diverse signaling molecules to orchestrate the behaviors of inflammatory cells, endothelial cells, keratinocytes, and fibroblasts [8] . In general, the progression of wound healing can be divided into four overlapping phases: hemostasis, inflammation, migration/proliferation and remodeling [7] . Hemostasis lasts for 2-3 hours, during which a fibrin plug is formed and cytokines and growth factors are released from the aggregated platelets. The inflammatory phase lasts from hours to days and is marked by the recruitment of neuotrphils and monocytes, which remove damaged tissues and combat infection. The migration/proliferation phase involves the invasion of endothelial cells, keratinocytes, and fibroblasts into the fibrin plug and through the processes of angiogenesis, epidermal resurfacing, and extracellular matrix (ECM) deposition produces granulation tissue, wound contraction, and closure. Remodeling, the last step in wound healing, can last several weeks and is marked by myofibroblast remodeling of ECM and the formation of scar tissue.
Wound healing in diabetes ( Fig. 1) is crippled by aberrant cellular phenotypes of essentially all participating cells and abnormalities in the expression and activity of cytokines and growth factors required for coordinating the healing process [2] . The pathogenic forces implicated are numerous, and include hyperglycemia [9, 10] , generalized chronic inflammation [11] , impaired neuropeptide signaling [12] [13] [14] , hypoxia [15] , and altered microcirculatory structure and reactivity [16, 17] . As a result, whereas acute wounds progress linearly through the phases of wound healing, chronic non-healing ulcers are unable to progress in synchrony and become stalled predominantly in the inflammatory phase [7] .
MOLECULAR

TARGETS FOR PROMOTING DIABETIC WOUND HEALING
We searched the Delphion patent database for patents filed within the last year with the keywords Diabetic Foot Ulceration and Diabetic Wound Healing. Corresponding patents were then reviewed for relevancy to identify those which make specific reference to the use of the patented technology in promoting wound healing. The molecular targets presented here (Table 1) were then classified into 4 different groups: immunomodulators, neuropeptides, growth factors and other agents. Each of these targets participates in one or more phases of wound healing. The immunomodulators primarily influence the inflammatory phase but also influence angiogenesis and remodeling. The neuropeptides regulate both the inflammatory as well as the angiogenic phase whereas the other agents predominantly affect angiogenesis. Targets classified as growth factors influence almost all phases of wound healing including hemostasis, inflammation, angiogenesis and remodeling.
IMMUNOMODULATORS
In the inflammatory phase of wound healing, there is sequential recruitment of immune cells followed by release of inflammatory chemokines and cytokines. Early on, aggregated platelets secrete platelet-derived growth factor (PDGF), a known chemokine and an important immunomodulator in wound healing. Recruitment of neutrophils and fibroblasts towards the PDGF gradient is a well known phenomenon [18, 19] . Once recruited to the wound site, neutrophils are a rich source of other inflammatory chemokines such as interleukin-8 (IL-8), interleukin-6 (IL-6) and macrophage chemotactic protein 1 (MCP-1), which are expressed within 4-12 hours post-wounding [20, 21] . In addition to these known and well studied immunomodulators, there have been reports about novel chemokines whose expression can regulate the function of immune cells and thereby enhance wound healing. Following is a summary of recent patents based on these novel immunodulators. 
DIABETES
Lactoferrin
Lactoferrin is an iron-binding protein found in large quantities in breast milk, and to a lesser extent in saliva, tears, bile, pancreatic fluid, and the secondary granules of neutrophils [22] . Lactoferrin has been identified as a complex immunomodulatory molecule, which exerts both positive and negative control of the immune system. First, lactoferrin exhibits direct antimicrobial properties through its ability to sequester iron and destabilize microbe membranes and is considered a key element in host defense that is released from neutrophils and mucosal epithelia [23, 24] . Second, lactoferrin demonstrates proinflammatory properties and can trigger the release of IL-8, tumor necrosis factor alpha (TNF-α), and nitric oxide from unstimulated macrophages [25] . However, lactoferrin also demonstrates anti-inflammatory properties and can suppress the release of TNF-α, interleukin-1 (IL-1), and IL-6 from endotoxinactivated immune cells [22] . In this regard, lactoferrin appears to serve as a normalizer of immune function, both contributing to the activation of the immune response from the resting state while also helping to neutralize an overabundant inflammatory response in the setting of potent immune cell activation. Lastly, lactoferrin has been shown to exhibit antineoplastic properties through the up-regulation of interleukin-18 (IL-18) and interferon-γ and has recently shown promise in cancer trials as an adjuvant to chemotherapy [26, 27] .
The majority of lactoferrin patent rights belong to Agennix, a company that holds over 90 patents pertaining to the production and use of talactoferrin. Talactoferrin is a recombinant human lactoferrin glycoprotein produced in the fungus Aspergillus niger and shown to retain the biological properties and functions of its natural counterpart [28, 29] . In 2004, Agennix filed a patent application covering the use of talactoferrin in the treatment of wounds [30] . Lactoferrin is known to increase the production of IL-18 from epithelial cells, and skin keratinocytes and Langerhans cells are an important dermal source of IL-18 that could be triggered by lactoferrin [31] . In wound healing, IL-18 is thought to attract neutrophils and macrophages to the wound site, thus contributing to the early inflammatory phase of healthy wound repair [32] [33] [34] . In addition, lactoferrin has been shown to drive angiogenesis by directly stimulating endothelial cell migration and proliferation, providing a second mechanism by which lactoferrin could be predicted to promote wound healing [35] . Lastly, lactoferrin contains an inherent advantage for ulceration treatment in that it is a natural endogenous effector found in high quantities in breast milk, and thus is likely to be safe for either oral or topical human exposure.
Currently, there are no peer-reviewed studies directly testing talactoferrin in models of wound healing, however, the Agennix patent application describes a number of dermal wound healing experiments performed by the company using mice. In these experiments, wound healing rates are said to have been increased in normal mice, diabetic mice, and in mice with infected wounds after either topical or oral administration of the compound [30] . Furthermore, wound healing rates are said to have exceeded those achieved in side-by-side comparison with becaplermin, a recombinant human PDGF which is presently the only biological treatment approved for chronic wounds [36, 37] . Lastly, Agennix has completed an NIH-sponsored multi-center phase II clinical trial evaluating topical talactoferrin treatment in diabetic neuropathic ulcers. Here, wound healing rates in the talactoferrin-treated group were nearly double those of the placebo group, however, the study was not sufficiently powered to reach significance (N = 16/group, P Connective tissue growth factor (CTGF) [165] Hepatocyte growth factor (HGF) [175] Other Agents Homeobox genes [181, 182] Treprostinil [189] = 0.09) [38] . Together, these studies provide encouraging data showing talactoferrin to be one of the most promising new compounds for the treatment of diabetic foot ulceration.
Thymosin beta 4
Thymosin beta 4 (Tβ 4 ) is a ubiquitous actin-sequestering molecule found in all eukaryotic cells which has been shown to promote wound healing in diverse models of corneal, dermal, and diabetic wounding [39] [40] [41] [42] . Tβ 4 is a 43-amino acid protein originally isolated in the thymus and later found to be induced during endothelial cell differentiation [43] . A role for the extracellular activity of Tβ 4 in wound healing has been suggested as high levels of Tβ 4 are present in platelets and wound fluid, leading to the hypothesis Tβ 4 is released from activated platelets at the site of tissue damage where it may modulate wound healing [44] . Tβ 4 administration has been shown to induce a plethora of favorable wound cell phenotypes, including increased endothelial cell and keratinocyte migration in vitro [40, 45] , and increased angiogenesis, keratinocyte migration, collagen deposition, and wound contraction in vivo [40, 42] . More recently, Tβ 4 was shown to up-regulate the expression of matrix metalloproteinases in wounds and wound cells, proteins required for wound debridement as well as ECM and collagen remodeling [46] . While the effects of Tβ 4 are clearly multi-faceted, we have classified it as an immunomodulator due to its complex effects on inflammatory processes. Initially, Tβ 4 was shown to exhibit antiinflammatory properties as it decreased neutrophil migration in vitro and inflammation-induced swelling in vivo [47] . However, it has also been shown to both up-regulate and down-regulate inflammatory cytokines at different time points after wounding in different models of corneal injury [39, 41] . While the pattern of Tβ 4 -induced inflammatory alteration remains incompletely understood, it is possible Tβ 4 could serve to up-regulate the early inflammatory burst required at the start of wound healing, while later suppressing the sustained inflammatory response characteristic of impaired wound healing.
The initial patent covering the use of Tβ 4 in wound healing was issued to the NIH in 1999 and has since been globally licensed to RegeneRx Biopharmaceuticals [48] . A recent European patent issued to the United States Health and Human Services describes the use of a topical or systemic medicament consisting of either the complete Tβ 4 peptide or the 7-amino acid actin-sequestering domain (LKKTET) for promoting wound healing through increased tissue repair, angiogenesis and cell migration [49] . Since the acquisition of patent rights, RegeneRx Biopharma-ceuticals has sponsored on-going phase I and phase II clinical trials testing Tβ 4 for the treatment of pressure ulcers, epidermolysis bullosa, and venous stasis ulcers [50] . No clinical trials have yet to be initiated specifically testing the benefits of Tβ 4 in diabetic wound healing, however, an obvious extension of Tβ 4 technology would be into this area.
T Cell immune response cDNA 7
T cell immune response cDNA 7 (TIRC7) was first described in 1998 as a novel T cell membrane protein upregulated after stimulation with alloantigen [51] . Additional study has shown TIRC7 to be present on both T and B cell membranes and has implicated TIRC7 in the regulation of T and B cell activation and T cell proliferation [51] [52] [53] . Based on these reports, translational research efforts have focused on the therapeutic utility of anti-TIRC7 antibodies in preventing organ rejection and autoimmune disease [51, 52, 54] .
Recently, the discoverers of TIRC7 patented the use of TIRC7 for both pro-and anti-angiogenic therapy [55] . In support of this function, the inventors describe new data identifying robust TIRC7 expression in proliferating capillary endothelial cells of tumors and thereby suggest a role for TIRC7 in the regulation of endothelial cell proliferation. From this finding, the inventors predict TIRC7 antagonists could be used as anti-angiogenic therapeutics in diseases such as cancer and diabetic retinopathy, whereas TIRC7 agonists could be used to promote angiogenesis in instances such as occlusive arterial disease, ischemic heart disease, and wound healing.
Although not yet characterized in models of diabetes, the immunomodulatory capacity and pro-angiogenic effects of TIRC7 could potentially be useful in promoting the wound healing response, and additional study of TIRC7 in models of diabetic wound healing would be encouraged.
Putative chemokines
Human Genome Sciences specializes in the discovery of new human genes and proteins for drug development [56] and recently patented two putative human chemokines for use in promoting wound healing. The first, deemed human chemotactic protein (HCP), was identified from an activated monocyte cDNA library [57] . The published cDNA sequence is predicted to encode a 119-amino acid protein with 27% identity and 56% similarity to human MCP-1 and contains a conserved four cysteine motif present in all chemokines [58] . MCP-1 is a powerful attractant of monocytes and macrophages produced by most wound healing cells and has been identified as an early mediator of acute injury and wound repair in dermal wounds [59, 60] . Given the similarity to MCP-1, the inventors predict HCP could prove useful in promoting wound healing, likely by potentiating the early inflammatory phase. The second putative chemokine discovered, deemed human chemokine beta-9 (Ckβ-9), was identified in a cDNA library derived from human breast lymph node tissue [61] . The published cDNA sequence is predicted to encode a 134-amino acid protein with 32% identity and 69% similarity to eotaxin, as well as the four cysteine chemokine motif. Eotaxin is a unique chemokine released from endothelial cells, smooth muscle cells, epithelial cells, and alveolar macrophages with the defining property of being a powerful chemoattractant for eosinophils [62] . Eotaxin has been implicated in the pathogenesis of asthma and other inflammatory conditions via the recruitment of eosinophils and profibrinogenic effect on fibroblasts [63, 64] . Although eosinophils are not currently considered key players in dermal wound healing, the inventors propose agonists of Ckβ-9 could be useful in recruiting cells for clearing debris and producing connective tissue, while antagonists of Ckβ-9 could help prevent excessive fibrosis [61] . Although HCP and Ckβ-9 represent new scientific leads for the development of diabetic wound healing technologies, the absence of any experimental data on the biological properties of HCP and Ckβ-9 proteins renders the future therapeutic utility of these molecules uncertain.
NEUROPEPTIDES
Diabetic neuropathy is characterized by the progressive loss of both somatic and autonomic nerve fibers and is one of the most common long-term complications of diabetes. Peripheral sensory neuropathy is reported in 30-50% diabetic patients and has been shown to be the most common and sensitive predictor for foot ulceration [65] [66] [67] . Recently, cutaneous neurobiology has gained much attention and multiple studies have shed light on the role of peripheral nerves in regulating skin processes such as wound healing. In the skin, signaling between the central and peripheral nervous systems in crosstalk with endocrine and immune systems leads to complex immunomodulation [68] . This complex interaction is mediated via neuromodulators such as neuropeptides, neurotransmitters, neurotrophins, and neurohormones. These neuromodulators bind to specific receptors and elicit downstream signaling in cell types in the skin, including endothelial cells, keratinocytes, mast cells, fibroblasts, and immune cells. In the presence of diabetic neuropathy, these signaling pathways may become impaired, contributing to the pathobiology of chronic foot ulceration. Here, we examine patents pertaining to the neuropeptides most commonly implicated in impaired wound healing, substance P and neuropeptide Y.
Substance P
Substance P (SP) is a 10-amino acid neurotransmitter widely distributed in the central and peripheral nervous systems [69, 70] . In the peripheral nervous system, SP is released from primary sensory neurons and neurons intrinsic to the gastrointestinal, respiratory, and genitourinary tracts [71] . The physiologic effects of SP are triggered through binding to its high affinity receptor, NK-1, which is present on a variety of cell types including immune cells, endothelial cells, neurons, epithelial cells and glial cells [71, 72] . Recently, a link between SP dysregulation and diabetes has been established. Serum levels of SP were shown to be decreased in patients with type I diabetes and especially in patients with diabetic neuropathy [73] . Furthermore, skin biopsies from both type I and type II diabetic patients showed a reduced density of SP nerve fibers [74] .
A role for SP in promoting wound healing was first shown in diabetic mice where fewer SP nerves were found in dermal wounds and exogenous treatment of the wound with SP shortened the wound closure time [75] . In an alternative model of wound healing, corneal wound healing rates were improved in diabetic rats using a combination of an SPderived peptide and insulin-like growth factor-1 [76] . The mechanisms through which SP is thought to modulate cutaneous wound healing are multi-faceted and include inflammatory, migratory, and proliferatory effects on wound healing cells. SP is released from peripheral neurons upon noxious stimuli such as burns or pressure. In endothelial cells, SP binds the NK-1 receptor leading to nitric oxide production, vasodilation, altered vascular permeability, and the recruitment and accumulation of leukocytes facilitating the expression of a local immune responses [77] . In addition, SP is produced by inflammatory cells such as macrophages, eosinophils, lymphocytes, and dendritic cells, and is a strong chemoattractant for lymphocytes, monocytes, neutrophils, and fibroblasts [78, 79] . By promoting vasodilatation, leukocyte chemotaxis, and leukocyte/endothelial cell adhesion, SP ensures the extravasation, migration, and subsequent accumulation of leukocytes at the site of injury. The accumulated leukocytes release cytokines creating a proinflammatory microenvironment which further stimulates endothelial cell proliferation and angiogenesis as well as endothelial cell, smooth muscle cell, and fibroblast migration [80] [81] [82] .
Two recent patent applications from separate groups describe the use of SP for promoting wound healing. The first, filed by inventors at Immuneregen Biosciences, aims primarily at using SP or SP analogs to treat impaired wound healing caused by irradiation, but also mentions the use of SP in surgical wounds, weapons wounds, bed sores and diabetic ulcers [83] . The patent application does not provide any mechanistic details by which SP is expected to heal irradiation wounds, however, SP has been shown to promote healing in irradiated wound models in the literature [12, 84] .
The second patent application describes the use of SP for facilitating cutaneous or corneal wound healing via the mobilization and proliferation of mesenchymal stem cells (MSCs) from the bone marrow [85] . In this application, the inventors describe a series of experiments demonstrating the first use of SP for MSC mobilization. In vitro, SP was shown to stimulate human MSC migration in a 3D collagen gel. Intravenous SP injection into non-wounded mice was then shown to mobilize approximately 15 times more CD29 + MSCs to the peripheral blood as compared to control mice. To test whether intravenously injected MSCs reach wound beds, labeled MSCs were transfused into the ear veins of rabbits in a corneal wound model. These cells were later found in the wound bed and improved corneal transparency, visual recovery, and corneal wound healing. Lastly, SP injection was shown to directly promote corneal wound healing in the rabbit model, presumably through the aforementioned mechanisms. In conclusion, this patent describes exciting and relevant data suggesting SP plays a signaling role as a wound healing initiator that mobilizes MSCs from the bone marrow to the wound site where they participate in wound healing.
Neuropeptide Y
Neuropeptide Y (NPY) is a highly conserved 36-amino acid polypeptide and is one of the most abundant neurotransmitters of the mammalian central and peripheral nervous systems. NPY has been shown to elicit diverse biological functions including hypothalamic control of food intake, anxiolysis, and sedation [86] . In the sympathetic nervous system, NPY is stored and co-released with norepinephrine and ATP from sympathetic nerve terminals and with epinephrine from the adrenal medulla. Release of NPY from these sites has been shown to contribute to vasoconstriction, vascular smooth muscle cell proliferation, and hypertrophy of ventricular cardiomyocytes [87] [88] [89] . NPY expression has further been identified in liver, heart, spleen, megakaryocytes and endothelial cells [90, 91] . NPY exerts its effects by activating members of the NPY receptor family of heptahelical G-protein coupled receptors. To date, four NPY Y receptor cDNAs have been cloned, Y1, Y2, Y4, and Y5 [92] .
Investigation into NPY expression in diabetes has shown NPY levels are reduced in patients with type I diabetes [93] . Recently, NPY expression was also shown to be reduced in diabetic rats, where both the number of neurons and densities of NPY immunostaining in the frontal cortex and hippocampus were decreased compared to control rats [94] . In another study, the vascular smooth muscle contractile response to NPY was significantly reduced in arteries isolated from diabetic rabbits [95] . With respect to wound healing, NPY has been shown to directly stimulate endothelial cell angiogenesis through receptor Y2 and Y5 signaling [96] [97] [98] , and deletion of the Y2 receptor in mice resulted in the blockage of NPY-induced angiogenesis and delayed wound healing [14] .
In 2005, Bayer HealthCare filed two similar applications broadly patenting the use of agonists or antagonists of the Y2 and Y5 receptors for human medical therapy [99, 100] . However, these patents are quite non-specific and provide no new data or discussion of NPY signaling in wound healing. Nonetheless, the emerging role of NPY in diabetic angiogenesis warrants further in vivo studies to evaluate the promise of NPY in promoting wound healing.
GROWTH FACTORS
Growth factors released from platelets, macrophages, neutrophils, fibroblasts, keratinocytes and endothelial cells are key participants in every phase of normal wound repair. Becaplermin, a recombinant human PDGF, is the first and only growth factor therapeutic approved for the treatment of diabetic foot ulcers. Although many growth factors have shown promising results in laboratory models of wound healing when used as single agents, the translation of these results to human patients has largely been unsuccessful. It is becoming apparent that given the complexity of the wound healing response with multiple interacting cell types and signaling pathways, use of a single agent may not be sufficient. Combining different growth factors or using growth factors in concert with other wound healing agents to treat chronic wounds may be a key strategy in achieving high rates of wound healing in the clinic. Here, we review recent patents describing the use of growth factors in promoting diabetic wound healing.
Vascular endothelial growth factor
The vascular endothelial growth factor (VEGF) family currently includes seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and placental growth factor (PlGF), all of which share a common VEGF homology domain of eight characteristically spaced cysteine residues. VEGF-A is the primary molecule involved in angiogenesis and vasculogenesis and causes proliferation, sprouting, migration and tube formation in endothelial cells [101] . VEGF is secreted by diverse cell types such as neutrophils, activated macrophages, keratinocytes and fibroblasts, and VEGF expression is strongly induced by hypoxia through the transcription factor hypoxia inducible factor-1 [102] [103] [104] . In addition, VEGF expression is induced by a host of common growth factors and cytokines, including epidermal growth factor, TGF-ß, keratinocyte growth factor, IGF-I, FGF, PDGF, TNF-α, IL-1B and IL-6 [105] [106] [107] .
VEGF has been identified as a critical inducer of angiogenesis during dermal wound repair and is dysregulated in diabetic wound healing [108] [109] [110] . In non-diabetic rabbits, VEGF expression was found to be powerfully up-regulated in wounds placed in both ischemic and non-ischemic skin [111] . However, VEGF expression was severely blunted after wound placement in diabetic mice [110] . Topical VEGF application has further been shown to promote wound closure in models of impaired wound healing. In mice, treatment with the angiogenesis inhibitor endostatin was shown to delay wound healing, but this effect was nearly completely reversed after application of topical VEGF [112] . In diabetic mice, topical VEGF application was found to accelerate cutaneous wound repair, in part by mobilizing and recruiting vascular progenitors [113] . Although to date there are no published clinical trials testing VEGF in diabetic wound healing, completion of such studies are expected in the near future. Indeed, in June of 2006 patient recruitment began for a multi-center, phase II, placebo-controlled trial sponsored by Genentech testing the effect of topical recombinant human VEGF on the healing of diabetic foot ulcers [114] .
In addition to the recombinant VEGF technology licensed to Genentech, four recent patents describe alternative methods for using VEGF to promote wound healing. The first application describes the discovery of VEGF-D and patents its use in either pro-or anti-angiogenic therapies [115] . There are no studies directly testing VEGF-D in wound healing, however, VEGF-D has been implicated in both angiogenesis and lymphangiogenesis [116] . The second patent from inventors at Human Genome Sciences describes the discovery of a new VEGF-like molecule, deemed VEGF-2, isolated from a cDNA library derived from an early stage human embryo at week nine [117] . This molecule was found to exhibit 30% homology to VEGF, including the conserved eight cysteine motif, and is said to promote endothelial cell migration and proliferation in cell culture. The inventors thus anticipate VEGF-2 could prove useful in stimulating wound healing or repairing vascular tissue. In the third patent, inventors from Stratech Corporation propose to engineer skin keratinocytes to inducibly express exogenous angiogenic growth factors, such as VEGF-A or angiopoietin-1, for use in autologous skin grafts [118, 119] .
Lastly, inventors from Sangamo Biosciences patented the use of zinc finger protein (ZFP) technology to enhance VEGF-A expression through the administration of custom designed ZFP chimeras that can bind and activate the VEGF promoter [120] . Zinc fingers are DNA binding motifs found in transcription factors which recognize specific sequences of DNA. Sangamo Biosciences has engineered de novo ZFPs that recognize short promoter elements of target genes, and coupled them with either transcriptional activators or repressors. In the Sangamo patent application, the inventors describe the development of eight ZFPs which bind the VEGF-A promoter and activate VEGF-A expression. Topical application of adenoviral constructs containing such ZFPs have been shown to increase VEGF-A expression, induce in vivo angiogenesis and promote wound healing in mice [121] . In another study, a VEGF-A ZFP was shown to improve diabetic neuropathy in rats after intramuscular administration [122] , and a phase I clinical trial is currently underway to evaluate the safety of the VEGF-A ZFP in patients with diabetic neuropathy [123] .
Fibroblast growth factor
Fibroblast growth factor (FGF) is a multifunctional member of the heparin-binding growth factor family known to promote the growth and differentiation of a spectrum of cell types, including dermal fibroblasts, keratinocytes, and endothelial cells. Stemming from mitogenic and angiogenic abilities, FGF has been implicated in tissue remodeling, wound healing, neovascularization and in promoting tumor growth and metastases. To date 22 different FGF proteins have been identified of which two forms, acidic-FGF (aFGF) and basic-FGF (bFGF), have been most thoroughly studied. Both aFGF and bFGF exert pro-angiogenic activity by interacting with various endothelial cell surface receptors. FGF activity is further augmented by a variety of free and ECM-associated molecules, VEGFs, and inflammatory cytokines, all of which play a role in the modulation of blood vessel growth in physiologic and pathological conditions [124] . bFGF has been shown to promote wound healing directly through the stimulation of endothelial cells and indirectly through the up-regulation of VEGF. Mounting evidence suggests such crosstalk and synergy between VEGF and bFGF is imperative for adequate angiogenesis [71, [125] [126] [127] .
Increased plasma levels of bFGF have been identified in diabetes [128, 129] , however, functional impairment of bFGF due to glycation has been shown overall to inhibit angiogenesis [130] [131] [132] . Strategies to replace functional bFGF by exogenous administration successfully accelerated wound healing in animal models of diabetes [133] [134] [135] [136] . In humans, a randomized, double-blind study found no benefit to topical bFGF application compared to placebo for healing diabetic neuropathic foot ulcers [137] . However, a second study found treatment of diabetic gangrene with a mixture of peripheral blood mononuclear cells and bFGF resulted in a dramatic improvement in healing rates [138] . The role of aFGF in wound healing is less well established, yet aFGF has been shown to accelerate the closure of excisional wounds in diabetic mice in multiple studies [139, 140] .
Based on the importance of FGF in promoting angiogenesis, three recent patents describe methods for the use of FGF or FGF variants to either enhance or suppress angiogenesis in the treatment of human disease. The first patent filed by the scientists who originally cloned bFGF in 1986 [141] patents the use of recombinant human aFGF and bFGF analogs for the promotion of wound healing and tissue repair [142] . A second patent filed by inventors at Zymogenetics identifies a new molecule, deemed zFGF-5, expressed highly in fetal and adult heart tissue and found to have homology with FGF-8 and patents its use in either proor anti-angiogenic therapy [143] . Finally, a third patent from inventors at Switch Biotech patents the use of FGF binding protein (FGF-BP) specifically for treating diabetic foot ulcers [144] . FGF-BP is a molecule which increases FGF bioavailability by releasing bound FGF from the ECM and has likewise been shown to be important in normal wound healing [145] . However, a clear link between FGF-BP and diabetic wound healing has not been made.
Nerve growth factor
Neurotrophins are trophic factors shown to prevent apoptosis and support regenerative capacity in cutaneous tissues and developing neurons. Nerve growth factor (NGF) was one of the first neurotrophins studied and has been tested in humans for efficacy in treating neuropathies of the central and peripheral nervous systems and more recently in healing human corneal and cutaneous ulcers [146] . Data supporting a role for NGF in wound healing includes the identification of marked NGF up-regulation in keratinocytes in angiogenic conditions such as psoriasis and wound repair [147] . NGF has further been shown to increase leukocyte accumulation, induce expression of endothelial cell adhesion molecules, promote endothelial cell growth and survival, and increase angiogenesis through a VEGF-mediated mechanism [147] [148] [149] [150] .
Increasing evidence suggests NGF is deficient in diabetes, as well as the associated neuropeptides SP and calcitonin gene-related peptide (CGRP) [151] . SP has been shown to induce NGF production from endothelial cells [152] , while reciprocally NGF has been shown to restore the diabetes-induced depletion of SP and CGRP in mice sensory neurons [153] . Studies testing the efficacy of NGF replacement in wound healing have shown administration of NGF accelerates the healing of experimentally induced wounds in normal and diabetic mice [154] [155] [156] and of diabetic foot ulcers in a small group of human patients [157] . In these studies, wound closure was shown to be enhanced through a combination of increased reepitheliazation, granulation tissue formation, and ECM deposition.
Based in part on these promising studies, inventors at a Danish Biopharmaceutical Firm recently patented the use of human cell lines engineered to overexpress bioactive NGF for use in healing diabetic foot ulcers [158] . The proposed technology utilizes an innovative encapsulated cell therapy approach whereby the engineered cells are placed within a semipermeable biocompatible material before implantation into the host tissue. This device would therefore allow for the free diffusion of secreted molecules out of the capsule while the cells themselves remain immunoisolated. Such a delivery strategy would entail some obvious translational challenges before clinical use, however, the ability to engineer cells to over-express multiple growth and healing factors simultaneously makes this approach appear exciting for future applications.
Connective tissue growth factor
Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family of proteins known to regulate chondrogenesis, angiogenesis, and fibrogenesis [159] . The most extensively characterized effects of CTGF are in fibroblast biology, where CTGF is thought to be a downstream mediator of TGF-β and has been shown to stimulate fibrosis and the formation of new connective tissue. CTGF is released from fibroblasts and leads to fibroblast proliferation and ECM deposition, and CTGF overexpression has been identified in a host of fibrotic diseases, including atherosclerosis, pulmonary fibrosis, scleroderma, and inflammatory bowel disease [160] . CTGF has further been identified in the formation of thrombi and is a secretory product of normal platelets released exogenously upon platelet activation. Platelets are then adherent to CTGF, suggesting this protein may be important at the sites of tissue injury or atherosclerotic plaque rupture [161] . Lastly, CTGF has been implicated in angiogenesis. It is produced by endothelial cells in response to angiogenic growth factors and has been shown to promote endothelial cell proliferation, migration, adhesion and survival [162, 163] .
Through these functions, CTGF has been hypothesized to play a role in normal wound healing, and high levels of CTGF have been identified in regenerating skin tissue and healing corneal wounds [164] . To date, there are no published studies directly evaluating the role of CTGF in diabetic wound healing, however, the actions of this molecule could theoretically be useful in promoting collagen release and granulation tissue formation. However, the continued expression of CTGF correlates with an overexuberant fibrotic response found in multiple disease states. Hence, careful in vivo study of CTGF application in wound healing, with close attention paid to side effects or other unintended consequences, would be warranted to determine if this target produces an overall beneficial or detrimental effect on healing wounds.
A recent patent from inventors at Human Genome Sciences describes the discovery and initial characterization of a novel human protein deemed CTGF-2 [165] . The sequence of CTGF-2 was identified in a cDNA library derived from human fetal lung and contains 49% identity and 67% similarity to mouse CTGF. The inventors further describe a number of experiments demonstrating this protein to be pro-angiogenic. Viral delivery of CTGF-2 is said to have increased microvascular endothelial cell migration, and administration in a rabbit hindlimb ischemia model is said to have increased tissue perfusion and revascularization more than a similar administration of VEGF-A. Hence, from these studies the inventors conclude CTGF-2 is a novel angiogenic molecule that could be administered to promote angiogenesis, primarily in limb revascularization.
Hepatocyte growth factor
Hepatocyte growth factor (HGF), also known as scatter factor, is secreted by cells of mesodermal origin and shows powerful proliferative and mitogenic activities in diverse cell types as well as angiogenic and angioprotective activities in endothelial cells, suggesting a role for HGF in the maintenance of normal endothelial cell function [166] [167] [168] [169] [170] . Evidence supporting a role for HGF in wound healing was shown convincingly in transgenic mice where HGF overexpression led to increased vascularization and granulation tissue formation in healing wounds and the local and systemic induction of VEGF [171] . In addition, recent studies have shown HGF is stored in the specific granules of neutrophils and can be released at sites of inflammation upon neutrophil degranulation. The release of HGF in this setting is therefore thought to contribute to normal tissue repair [172] . Decreased biological activity of endogenous HGF was further identified in chronic skin ulcers in human patients, allowing the possibility of HGF restoration for improving wound healing in non-healing ulcers [173] .
Initial studies testing the effect of HGF supplementation on wound healing have been performed in animal models and clinical trials. In diabetic mice, topical recombinant human HGF application promoted wound repair by increasing granulation tissue formation, wound angiogenesis, and reepitheliazation [76, 174] . Experimental data provided in a recent patent application covering the use of HGF in medical therapy describes increased angiogenesis in excisional wounds placed in pigs treated locally with HGF [175] . In humans, clinical trials with HGF have been performed in patients with chronic leg ulcers and in patients with foot ulcers in the setting of non-operable critical leg ischemia. While neither of these settings directly addresses the problem of the diabetic foot, both provide related evidence for the efficacy of HGF in healing chronic wounds where many of the factors leading to ulceration are similar to diabetes. In the first study testing topical HGF application on wounds in elderly patients with chronic leg ulcers, HGF led to high wound healing rates presumably by improving microcirculatory perfusion [176] . However, this small pilot study was not placebo-controlled, and a later note by the authors suggests these results were not substantiated by further studies [177] . In a second set of trials sponsored by AnGes, Inc., intramuscular injection of naked HGF plasmid DNA in patients with non-operable critical leg ischemia and foot ulceration was tested in both phase I and phase II clinical trials [178, 179] . Although both trials indicate the regimen was safe and well-tolerated, a statistically significant effect on wound healing was not demonstrated [180] .
OTHER AGENTS Homeobox Genes
Extensive research from investigators at the University of California San Francisco has explored the biological function and therapeutic utility of homeobox genes in diabetic wound healing, resulting in multiple patents describing the use of genes HoxD3, HoxB3, HoxA3, and HoxD10 in wound healing therapy [181, 182] . The homeobox genes are a family of master transcription factors found to be highly expressed during embryogenesis, skin development, and fetal wound healing [183] .
HoxD3, the first homeobox gene studied in wound healing, is believed to be essential for normal wound repair and is dysregulated specifically in diabetic wounds. Initial in vitro studies found HoxD3 promoted angiogenesis and collagen synthesis in cultured endothelial cells [184, 185] . HoxD3 levels were then shown to be rapidly and stably upregulated in endothelial cells neighboring dermal wounds in normal adult mice, but not in diabetic mice [185] . This general expression pattern appears to have been confirmed in a small sample of human patients, with the added finding that HoxD3 levels are blunted in diabetic foot ulcerations but not in chronic venous ulcers, suggesting a unique relationship between HoxD3 and wound healing that is specific to diabetes and not to other forms of chronic wounds [181, 182] . Lastly, HoxD3 was shown to promote wound healing through the mechanisms of increased angiogenesis and collagen deposition in diabetic mice after a single application of a HoxD3 DNA-impregnated methylcellulose patch. Here again, the authors note wound healing rates were unchanged after similar application to wild-type animals where HoxD3 levels are not suppressed [183] . Together, these data appear to identify a novel molecular alteration unique to the pathogenesis of diabetic wound healing that can be reversed to help restore the normal wound healing response.
Additional work from this group has focused on the related homebox genes HoxB3, HoxA3, and HoxD10 in the wound healing process. HoxB3 and HoxA3 are paralogues of HoxD3 and are thought to serve complementary and sometimes overlapping functions [186] . HoxB3 has been shown to promote capillary morphogenesis and angiogenesis in vitro and in vivo [187] , however, HoxB3 expression was not significantly induced in normal wound repair or altered between wounds created in normal and diabetic mice [185] . Nonetheless, data included in a 2005 patent application describes a marked increase in wound healing in diabetic mice after application of HoxB3 DNA-impregnated patches, superior to the wound healing rates achieved by HoxD3 DNA patches [182] . Completing the trend, recent data published in the peer-review literature describes the role of HoxA3 in wound healing and shows HoxA3 is up-regulated in microvessels after injury, promotes angiogenesis, enhances reepitheliazation, and again achieves wound healing rates in diabetic mice superior to HoxD3 after single application gene transfer [182, 186] . Lastly, investigation into a fourth homeobox gene, HoxD10, revealed an opposite biological function in wound healing. HoxD10 was shown to promote a quiescent, nonangiogenic phenotype in endothelial cells [188] , and correspondingly, data presented in the patent applications indicate the delivery of HoxD10 DNA to diabetic wounds further impaired the wound healing response [181, 182] . Accordingly, the inventors propose the use of HoxD10 inhibitors for the promotion of diabetic wound repair.
Treprostinil
Treprostinil is a stable prostacyclin analog, marketed under the trade name Remodulin®, approved for the treatment of pulmonary hypertension via continuous subcutaneous infusion. In 2005, the makers of treprostinil patented its use for the treatment of neuropathic diabetic foot ulcers [189] . Prostacyclin is a potent vasomodulator released primarily by endothelial cells which has been shown to stimulate peripheral vasodilation, decrease pulmonary vascular resistance, inhibit platelet aggregation, and inhibit smooth muscle cell proliferation [190] .
Vascular disease in diabetes is characterized by impairment at both the macro-and microcirculatory levels. Large vessel disease in diabetics is similar to the atherosclerotic changes found in non-diabetics with the only exception being it has a propensity to occur in the infrageniculate arteries of the calf [191] . In contrast, the diabetic microcirculation has no occlusive lesions, but is instead limited primarily by functional impairments in endothelialand smooth muscle cell-mediated vasodilation [17] . The vasodilatory effects of prostacyclin could therefore be predicted to help restore the diminished vascular reactivity of the diabetic microcirculation while having little effect on reversing occlusive macrovascular dysfunction. Consistent with this prediction, evidence suggests prosta-cyclin analogs are ineffective in promoting wound healing in the setting of severe large vessel disease [192] . Correspondingly, the inventors of treprostinil emphasize the difference between neuropathic and neuroischemic ulcers, and specifically promote the use of treprostinil for the treatment of the former [189] . Neuropathic ulcers are described as painless ulcers that appear on the edges or the sole of the foot in the setting of adequate distal blood flow. This type of ulcer is primarily caused by impaired wound healing due to microcirculatory dysfunction and sensory neuropathy, and would be more amenable to treatment with the use of a small vessel vasodilator. In contrast, neuroischemic ulcers are described as painful ulcers of the toes that appear in the setting of severe ischemia with diminished distal pulses. In these cases, the primary impairment leading to ulceration is large vessel occlusion, and prostacyclin would not be expected to have a therapeutic effect.
To date, there are no peer-reviewed studies testing the use of treprostinil in diabetic wound healing. However, reports have shown accelerated dermal wound healing through the mechanisms of improved angiogenesis and blood flow in diabetic mice after the topical application of a related prostacyclin analog [193] . In addition, the patent application describes three small trials in which treprostinil was shown to improve diabetic wound healing. In the first, 7 patients with diabetes, peripheral arterial disease, and inoperable ischemic foot ulcers are said to have experienced improved ulcer resolution and leg pain after subcutaneous treprostinil infusion for 12 weeks. In the second, 7 patients with diabetes, non-healing wounds, and critical ischemia are said to have shown improvement in wound oxygenation, blood flow, and wound healing after subcutaneous treprostinil infusion for 6 weeks. In the third, an undisclosed number of diabetic patients with at least one neuropathic ulcer are said to have experienced improved ulcer resolution after subcutaneous treprostinil infusion for 12 weeks [189] . However, there are no published trials to substantiate these claims.
CURRENT & FUTURE DEVELOPMENTS
Wound healing has matured as a research field over the last two decades. The main progress involved the understanding of the physiology of normal wound healing and, at least partially, the pathophysiology of chronic wounds, such as diabetic foot ulcers. Over the last decade, the efficacy of single growth factors has been tested and the success can be characterized as modest, at the best. The challenge of the next decade is first to fully understand the pathophysiology of chronic wounds and the role of various cytokines and growth factors. The second step will be to develop therapies that will employ different matrices, cytokines and growth factors that will be delivered on a timely fashion that resembles normal wound healing and will, hopefully, promote wound healing to levels that are observed in healthy, non-diabetic subjects.
